Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Acronyms MEASURE 2
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 04 Jun 2022 Results of post-hoc analysis evaluating key clinical symptoms at baseline through Wk 260, presented at the 23rd Annual Congress of the European League Against Rheumatism
- 01 Feb 2022 Results of post-hoc pooled analysis of 3 secukinumab studies (MEASURE 2,-3 &-4) assessing -term NSAID-sparing effect of secukinumab over 4 years in patients with r-axSpA, published in the Rheumatology International.
- 09 Nov 2021 Results of pooled post-hoc analysis assessing efficacy of secukinumab in patients with oligoarticular PsA by using data from five phase III studies presented at the ACR Convergence 2021